Advertisement
CVM vs NRXS
Which Stock Would AI Choose? CEL-SCI Corporation (CVM) vs. NeurAxis (NRXS) Stock Comparison
Key Takeaways
- CVM (CEL-SCI Corporation) is a clinical-stage cancer immunotherapy company with no meaningful revenue, while NRXS (NeurAxis, Inc.) is a commercial-stage medical device firm posting triple-digit revenue growth.
- Recent weeks have favored NRXS on operating momentum, driven by a new Category I CPT code (a standardized medical billing code) for its IB-Stim technology, while CVM remains dependent on clinical and regulatory catalysts.
- CVM recently raised roughly $7.2 million in a public offering and saw insider buying from its CEO, signaling management confidence despite ongoing losses.
- NRXS grew revenue 80% year over year in its latest quarter and expanded gross margin above 86%, reflecting improving reimbursement and payer coverage.
- The two stocks carry very different risk profiles: a binary, catalyst-driven biotech versus a scaling med-tech business with recurring, commercialized revenue.
- For more detail on each company's latest developments and intraday action, explore the CVM Major News and CVM Today's Price Move pages, along with the NRXS Major News and NRXS Today's Price Move pages.
- To see how automated strategies are positioning across the market, visit Tickeron's Trending AI Robots.
Introduction
Investors weighing speculative healthcare names often compare companies at very different stages of maturity. CVM (CEL-SCI Corporation) and NRXS (NeurAxis, Inc.) both trade on the NYSE American exchange and both operate in the broader healthcare sector, but their business models, revenue profiles, and market positioning diverge sharply. This stock comparison is relevant for traders and investors evaluating relative performance between a pre-revenue, catalyst-driven biotech and a commercial-stage medical technology company. By examining recent momentum, risk factors, and growth drivers, readers can better understand how each name fits within a diversified healthcare portfolio and which one currently displays more favorable market positioning.
CVM Overview and Recent Performance
CVM is CEL-SCI Corporation, a clinical-stage cancer immunotherapy company developing Multikine (Leukocyte Interleukin, Injection), a treatment designed to stimulate the immune system against tumors before surgery, radiation, or chemotherapy. The company has no material commercial revenue and finances operations primarily through equity raises.
In recent weeks, CVM has focused on advancing Multikine toward potential commercialization. The company priced and closed a best-efforts public offering of 6 million shares at $1.20 per share, generating gross proceeds of approximately $7.2 million, to fund continued development of Multikine and general corporate purposes. Management also highlighted a strategic partnership in Saudi Arabia and preparations for a U.S. FDA (Food and Drug Administration) confirmatory registration study. Notably, the company's CEO purchased additional shares following the financing, which market participants often interpret as a sign of insider confidence.
Despite these developments, CVM remains a high-risk, pre-revenue asset. Its share price has experienced substantial volatility over the past year, and equity dilution from capital raises has weighed on sentiment even as clinical data presentations have periodically sparked interest.
NRXS Overview and Recent Performance
NRXS is NeurAxis, Inc., a commercial-stage medical technology company developing neuromodulation therapies for chronic conditions in children and adults. Its flagship product, IB-Stim, uses Percutaneous Electrical Nerve Field Stimulation (PENFS) to treat functional abdominal pain and related gut-brain disorders.
Recent market activity has been shaped by a pivotal reimbursement milestone: a Category I CPT code (a permanent medical billing code issued by the American Medical Association) for PENFS took effect at the start of 2026, substantially expanding payer coverage. In its latest reported quarter, NRXS posted revenue of $1.6 million, up 80% year over year, with gross margin expanding to 86.4%. A subsequent quarter showed even stronger growth, with revenue rising roughly 116% year over year, though the stock pulled back after earnings as operating losses widened on commercialization spending.
Operationally, NRXS has secured new payer coverage, a Veterans Affairs Federal Supply Schedule contract, and expanded FDA clearances for IB-Stim. These developments position the company for continued revenue growth, though profitability and cash-flow breakeven remain forward-looking goals.
Trending AI Robots
For investors who prefer a data-driven approach to stock selection, Tickeron's Trending AI Robots page curates the platform's most compelling automated trading strategies. Tickeron hosts hundreds of AI Trading Bots that collectively monitor thousands of tickers, but only a select subset earns a place in this curated section. These robots span diverse trading styles, timeframes, performance statistics, and ticker universes, allowing users to evaluate strategies that align with their own objectives. The Trending section highlights bots that are currently most suitable for prevailing market conditions, providing a useful lens for comparing names like CVM and NRXS. Explore the Trending AI Robots page to review available bots and their performance metrics.
Head-to-Head Comparison
The most fundamental contrast between CVM and NRXS is stage of development. CVM is a pre-revenue biotech whose valuation rests almost entirely on clinical trial outcomes and regulatory decisions for Multikine. Its growth drivers are binary and catalyst-driven, and its financing needs create ongoing dilution risk. By contrast, NRXS generates actual product revenue with high gross margins, and its growth is tied to the more predictable expansion of insurance coverage and physician adoption.
On risk factors, CVM faces execution and capital-access risk, while NRXS faces the challenge of converting reimbursement wins into sustained volume and ultimately profitability. Market sentiment has generally rewarded NRXS's visible revenue trajectory, while CVM's share price has been more volatile and sensitive to financing events. In terms of sector exposure, both are healthcare names, but CVM sits in oncology immunotherapy while NRXS operates in pediatric and adult neuromodulation devices.
Tickeron AI Verdict
Based on observable factors such as trend consistency, revenue visibility, and relative positioning, Tickeron's AI would likely favor NRXS over CVM in the current environment. NRXS offers a more established, recurring revenue base with expanding reimbursement support and improving gross margins, characteristics that tend to align with more stable technical and fundamental signals. CVM, while potentially offering higher upside on positive clinical catalysts, carries greater uncertainty and volatility. This assessment is probabilistic rather than definitive, reflecting the relative strength of observable trends rather than a guaranteed outcome.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVM is a Hold and NRXS is a Hold.
Momentum Indicator for CVM turns negative, indicating new downward trend
CVM saw its Momentum Indicator move below the 0 level on October 13, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 97 similar instances where the indicator turned negative. In 92 of the 97 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CVM turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 40 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CVM moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CVM crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CVM entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CVM's RSI Indicator exited the oversold zone, 34 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 61 of 77 cases where CVM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +4.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVM advanced for three days, in 175 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
CVM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. CVM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.328) is normal, around the industry mean (3.498). P/E Ratio (-0.858) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.370) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NRXS in upward trend: price may jump up because it broke its lower Bollinger Band on November 05, 2026
NRXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 27 cases where NRXS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 29 of 35 cases where NRXS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
Following a +8.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXS advanced for three days, in 123 of 147 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NRXS as a result. In 61 of 68 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NRXS turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 30 similar instances when the indicator turned negative. In 27 of the 30 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
NRXS moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NRXS crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. NRXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.641) is normal, around the industry mean (3.498). P/E Ratio (-8.211) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (14.225) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CVM | ||
|---|---|---|
OUTLOOK RATING 1..100 | 57 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 65 | |
P/E GROWTH RATING 1..100 | 63 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CVM | NRXS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | N/A |
| Stochastic ODDS (%) | 2 days ago 79% | 2 days ago 83% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| Advances ODDS (%) | 27 days ago 79% | 3 days ago 84% |
| Declines ODDS (%) | 7 days ago 90% | 9 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 77% | 2 days ago 89% |
| Aroon ODDS (%) | 2 days ago 90% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CVM’s FA Score shows that 0 FA rating(s) are green while NRXS’s FA Score has 1 green FA rating(s).
- CVM’s FA Score: 0 green, 5 red.
- NRXS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CVM’s TA Score shows that 4 TA indicator(s) are bullish while NRXS’s TA Score has 3 bullish TA indicator(s).
- CVM’s TA Score: 4 bullish, 6 bearish.
- NRXS’s TA Score: 3 bullish, 5 bearish.
Price Growth
CVM (@Biotechnology) experienced а 0.00% price change this week, while NRXS (@Biotechnology) price change was -5.02% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
CVM is expected to report earnings on Jan 04, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NRXS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NRXS has been loosely correlated with CVM. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if NRXS jumps, then CVM could also see price increases.
| Ticker / NAME | Correlation To NRXS | 1D Price Change % | ||
|---|---|---|---|---|
| NRXS | 100% | -5.45% | ||
| CVM - NRXS | 58% Loosely correlated | +4.44% | ||
| TWST - NRXS | 28% Poorly correlated | -2.37% | ||
| CRBP - NRXS | 27% Poorly correlated | +11.65% | ||
| PVLA - NRXS | 27% Poorly correlated | -3.08% | ||
| NTLA - NRXS | 27% Poorly correlated | -7.76% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| LRCU | 22.49 | 0.21 | +0.94% |
| Tradr 2X Long LRCX Daily ETF (LRCU) | |||
| FYEE | 29.37 | N/A | N/A |
| Fidelity Yield Enhanced Equity ETF (FYEE) | |||
| GXPC | 27.26 | -0.03 | -0.11% |
| Global X PureCap MSCI Communication Services ETF (GXPC) | |||
| KLMT | 34.10 | -0.18 | -0.53% |
| Invesco MSCI Global Climate 500 ETF (KLMT) | |||
| EUVX | 8.22 | -0.15 | -1.75% |
| Corgi Lithography & Semiconductor Photonics 2x Daily ETF (EUVX) | |||